Thin
1 / 2
Orforglipron is an investigational oral medication being developed by Eli Lilly for treating type 2 diabetes and obesity. It is a non-peptide GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that regulates blood sugar and appetite. Clinical trials have shown that orforglipron can lead to significant weight loss and improved blood sugar control in people with type 2 diabetes and obesity.
Orforglipron is a novel GPR40 (FFAR1) agonist, designed to enhance insulin secretion in response to elevated glucose levels. By selectively activating GPR40 receptors in pancreatic β-cells, Orforglipron improves glucose-dependent insulin release, potentially offering benefits in type 2 diabetes management. Early clinical data suggest improvements in glycemic control, HbA1c reduction, and beta-cell function, making it a promising candidate for research and development.
In original research studies, Orforglipron has been administered as an oral tablet, with doses typically ranging from 10 mg to 50 mg per day, adjusted according to clinical trial protocols and patient response. Dosage may vary in experimental studies, and all applications should follow ethical and regulatory guidelines.
Orforglipron is subject to ongoing patent filings. A preparation method for the GLP‑1 receptor agonist Orforglipron has been published under Chinese patent application CN117964617A (filed December 29, 2023, pending). Additional intellectual property protections, including formulation, synthesis, and method‑of‑use patents, are under development and may be pursued globally as the program advances.
Orforglipron is manufactured under strict cGMP conditions at ThinHeal’s Shaoxing facility, ensuring batch-to-batch consistency, high purity, and stability. Comprehensive quality testing is performed for identity, assay, pH, and solubility to guarantee research-grade standards.
